ADCT — Adc Therapeutics Share News
0.000.00%
Last trade - 00:00- $190.22m
- $387.28m
- $81.36m
Brief: ADC Therapeutics Q4 Net Income USD -30.727 Million
ADC Therapeutics SA expected to post a loss of 41 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 42 cents a share - Earnings Preview
Brief: Adc Therapeutics Announces Completion Of Enrollment Of Phase 3 Confirmatory Clinical Trial Of Zynlonta In Combination With Rituximab In 2L+ Diffuse Large B-Cell Lymphoma
Brief: ADC Therapeutics Announces Positive Initial Data From Lotis-7 Clinical Trial Evaluating Zynlonta® In Combination With Bispecific
Brief: ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
ADC Therapeutics SA reports results for the quarter ended September 30 - Earnings Summary
ADC Therapeutics SA expected to post a loss of 38 cents a share - Earnings Preview
ADC Therapeutics SA reports results for the quarter ended in June - Earnings Summary
ADC Therapeutics SA reports results for the quarter ended in March - Earnings Summary
Brief: ADC Therapeutics Announces Initial Data From Investigator-Initiated Phase 2 Clinical Trial Of Zynlonta In Patients With Relapsed/Refractory Marginal Zone Lymphoma
ADC Therapeutics SA expected to post a loss of 56 cents a share - Earnings Preview
Brief: ADC Therapeutics Announces Updates On Lotis-7 Clinical Trial Evaluating Zynlonta® In Combination With Glofitamab Or Mosunetuzumab In Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Brief: ADC Therapeutics SA Files For Common Stock Offering Of Up To 4.4 Million Common Shares By Selling Shareholders - SEC Filing
ADC Therapeutics SA reports results for the quarter ended in December - Earnings Summary
ADC Therapeutics SA expected to post a loss of 50 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 50 cents a share - Earnings Preview
Brief: ADC Therapeutics Says Co & Certain Of Its Subsidiaries Entered Into First Amendment To Loan Agreement & Guaranty, Dated Aug 15, 2022
Brief: ADC Therapeutics Provides Business Updates